Benzinga | Feb 10, 2021 10:05AM EST

Chardan Capital Maintains Buy on Editas Medicine, Raises Price Target to $77

Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $55 to $77.